How $1 billion deal with San Francisco biotech could change how we prep for flu season


The company has been without a product on the market since the FDA withdrew emergency use authorization in April of its Covid 19 treatment as the Covid virus mutated.

Previous Financial services firm moves to bigger headquarters in Fort Lauderdale
Next Homes are taking longer to sell in metro Denver while the buyer-seller balance is shifting